# Neumirna Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neumirna-therapeutics-aps

- Industry: Pharmaceuticals
- Headquarters: Copenhagen, Denmark
- Website: www.neumirna.com
- Total disclosed funding: $21M
- Latest round: Series A (Jan 8, 2025)
- Investors on record: 3

## About

Founded in 2020, and based in Copenhagen, Denmark, Neumirna Therapeutics ApS operates as a pharmaceutical company that engages in the development of RNA therapies. In January 2025, Neumirna Therapeutics raised EUR 20 million in series A funding co-led by investors Angelini Ventures and Invivo Partners, with participation from another investor Innovestor. The firm as of January 2025, is led by its CEO, Janine Erler.

The company's RNA therapies effectively modifies the course of neurological disorders, including epilepsy. Their core product, NMT.001, targets specific molecular pathways involved in these conditions. The company employs advanced RNA therapeutic technologies to create transformative solutions for patients requiring disease modification, with end users primarily being patients suffering from various neurological disorders.

The company plans to utilize the January 2025 funding to expand its research and development.

## Funding rounds

- Series A, Jan 8, 2025, $21M — Innovestor, Invivo Partners, Angelini Ventures

## Investors

- Innovestor (https://capitalatlas.ai/funds/innovestor) — Series A
- Invivo Partners (https://capitalatlas.ai/funds/invivo-partners) — Series A
- Angelini Ventures (https://capitalatlas.ai/funds/angelini-ventures) — Series A